// App-Quantinova.ai

2365 : Checkpoint inhibitors and a multivalent melanoma vaccine as a novel combinatorial therapy

Researchers

Presenter

  • Rachana R. Maniyar

Principal Investigators

  • Neha Tuli

  • Robert Suriano

  • Jan Geliebter

  • Marc Wallack

  • Raj K. Tiwari

Medical Centers

  • New York Medical College, Valhalla, NY

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Skin carcinoma

  • Melanoma

  • Solid malignancies

Biomarkers

  • New York esophageal squamous cell carcinoma 1

  • B-Raf proto-oncogene, serine/threonine kinase

  • Phosphatase and tensin homolog

  • Cytotoxic T-lymphocyte-associated protein 4

  • Interleukin-2

  • Melanoma Cell Adhesion Molecule

Drug/Treatment

  • Ipilimumab

  • Vemurafenib

  • TRP-1

  • GP100

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved